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Abstract
Aim. The research of antimicrobial and toxicological parameters of a promising pharmaceutical composition with indole-3-car-
binol and meloxicam in the form of rectal suppositories.
Materials and methods. The research of antimicrobial activity was carried out in vitro by diffusion in nutrient agar in the 
modification of “holes” on the reference strains of common pathogens Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia 
coli, Bacillus subtilis, Candida albicans.
Adult rats were used for the study of acute toxicity. Suppository mass were administrated in the largest possible volume rectally 
or orally. The animals were periodically monitored according to the experimental plan – the assessment of physiological parameters 
before administration and after 6, 12, 18, 24 hours, at 3, 7 and 14 days. The animals were removed from experiment and necropsy pro-
vided after 1, 3, 7, and 14 days.
Results. The sizes of zones of inhibition of the microorganisms growth were most significant (from 19.27±0.61 mm of E. coli 
to 40.80±0.42 mm of S. aureus) near sample of the combined composition suppository compared with other combination of active sub-
stances and excipients.
During the observation of animals for 14 days and the study of internal organs after autopsy, deviations in physiological (weight, 
temperature, activity, respiratory rate) and macroscopic morphological indicators of animals from reference values were not detected.
Conclusion. According to the results of microbiological studies, a moderate antimicrobial effect of suppositories of combined 
composition in relation to all the studied pathogens was revealed. The absence of manifestations of acute toxicity allows us to conclude 
that the pharmaceutical composition can be classified as practically non-toxic substances.
The obtained results allow us to recommend a pharmaceutical composition with indole-3-carbinol and meloxicam on a 
polyethylene oxide basis in the form of suppositories for further preclinical studies of specific pharmacological effects as a prostate 
protective agent.
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1. Introduction
The metabolite of plant glucosinolates indole-3-carbinol (I3С) is a promising treatment for 
prostate diseases [1]. The effectiveness of I3С as a component of complex therapy of hormone-de-
pendent diseases of benign prostatic hyperplasia (BPH), prostate carcinoma, uterine fibroids, fibro-
cystic mastopathy is confirmed. Experimentally demonstrated high antitumor activity of I3С and 
its metabolite DIM with respect to prostate cancer [2], the ability to induce cell apoptosis, inhibit 
the growth of androgen-dependent and androgen-independent cell cultures of this gland [3]. As 
well as the ability to block the proliferation of signals (in particular, the activation of nuclear tran-
scription factor NF-kB and protein kinase Akt [4]) in prostate cells by inhibiting the expression 
of androgen receptors, which play an important role in the pathogenesis of BPH [5]. I3С exerts a 
modulating effect on estrogen receptors (ER) and the number of androgen receptors (AR) [6] Based 
on its pharmacodynamic characteristics, it can be assumed that I3С may have a complex effect on 
the mechanisms of BPH and CP.
Useful for the treatment of prostatitis is the antimicrobial activity of I3С, as there are reports 
that the substance exhibits broad-spectrum antibacterial activity, in particular, in Candida albicans, 
I3С stops the cell cycle in phase G(2)/M, thus destroying the structure of the cell membrane of 
C. albicans [7].
Diseases of the gland are also characterized by an increase in the activity of cytokines, 
growth factors, cyclooxygenase (COX) type 1 and 2, inducers of angiogenic, anti-apoptotic and 
inflammatory processes. It is believed that the inhibition of inflammation may reduce the risk of 
prostate disease. It is therefore important that I3C exhibits antimicrobial, anti-inflammatory, anti-
oxidant properties.
Non-steroidal anti-inflammatory drugs (NSAIDs) have a more specific anti-inflammatory 
effect. They are widely used in the world because of their antinociceptive, anti-inflammatory ef-
fects, particularly in cancer and other prostate diseases, although there is still no consensus on the 
usefulness of NSAIDs in prostate diseases, but they believe this to be the case for treating BPH and 
prostate cancer [8]. With the use of NSAIDs, COX-1 and COX-2 inhibitors reduce the symptoms 
of inflammation and improve the quality of life of patients with chronic prostatitis [9], reduce the 
risk of BPH development and progression [10]. In clinical studies, it has been shown that, with the 
use of NSAIDs, a greater reduction in the average international prostate symptom score and faster 
relief of BPH symptoms have been observed [11], thought to be due to a decrease in viability and 
inhibition of BPH cell line proliferation [12].
A combination of I3C and a non-steroidal anti-inflammatory drug is considered to be ap-
propriate to increase the efficacy of the drug and expand the range of pharmacological effects and 
indications for use. Meloxicam is a selective cyclooxygenase type 2 inhibitor with pronounced 
anti-inflammatory properties due to inhibition of arachidonic acid metabolism. He is thought to be 
at lower risk of damage to the gastric mucosa [13], although there is a risk of cardiovascular events, 
especially with prolonged treatment [14]. 
That is why, when designing new highly effective drugs, the dosage form is important, 
which provides optimal therapeutic effect with minimal side effects. The use of rectal supposito-
ries as the optimal dosage form is relevant for the problem of prostate treatment [15]. They have 
several advantages over other dosage forms: independence of the completeness of absorption from 
the functional state of the gastrointestinal tract; the maximum part of the dose of the drug bypasses 
the processes of presystemic metabolism and invariably enters the prostate; high absorption rate 
(comparable to parenteral routes of administration), in most cases no allergic effect on the body; 
independence of the input path from the state of other systems; ease of use; metering accuracy. This 
is confirmed by studies of local reaction, safety and efficacy of meloxicam suppositories (15 mg) 
over 3 weeks, which showed no significant adverse events, and approximately 90 % of people rated 
meloxicam response and treatment efficacy as good or very good [16].
During the research, the authors proposed the optimal composition of a promising pharmaceu-
tical composition for the treatment of prostate diseases in the form of rectal suppositories with I3C and 
meloxicam. To compare the efficacy of the release of the active substances from the two variants of 
the suppository base (solid fat and polyethylene oxide (PEO)), a screening study was performed on a 
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model of turpentine prostatitis [17]. The availability of the active components was determined by the 
degree of inhibition of inflammation and the effect on the hormonal background of the animals. Because 
PEO-based suppositories had a more pronounced effect on the course of the inflammatory process and 
reduced serum testosterone content, they were selected as a promising drug for further in-depth phar-
macological research including the determination of acute toxicity and antimicrobial activity.
Aim of the research. Microbiological and toxicological study of a new preparation in the 
form of rectal polyethylene oxide-based suppositories (SCS-PEO) containing indole-3-carbinol and 
meloxicam.
2. Materials and methods
In the study of the antimicrobial properties of SCS-PEO, as the substances were used 
meloxicam (BoehringerIngelheimGmbH, Germany) and I3C (Sigma-Aldrich Co., USA), as well as 
samples of some variants of suppositories of the following composition:
– Sample 1 – PEO-base: a mixture of PEO-1500 and PEO-400 (95:5); Montanox 80 (Poly-
sorbate-80);
– Sample 2 – PEO basis; Montanox 80; indole-3-carbinol (0.2 g/suppository);
– Sample 3 – PEO basis; Montanox 80; meloxicam (0.0075 g/suppository);
– Sample 4 – SCS-PEO;
– Sample 5 – PEO basis; indole-3-carbinol (0.2 g/suppository);
– Sample 6 – PEO basis; indole-3-carbinol (0.2 g/suppository); meloxicam (0.0075 g/1 sup-
pository).
Microbiological study was performed on clinically significant pathogens of inflammatory dis-
eases of the genitourinary system (including prostatitis). The reference strains of bacteria and fungi 
were taken from the Ukrainian Collection of Microorganisms of the Institute of Microbiology and 
Virology named after I. V. Zabolotnyi (Kyiv, Ukraine): Staphylococcus aureus (ATCC 6538), Pseu-
domonas aeruginosa (ATCC 9027), Escherichia coli (ATCC 8739), Bacillus subtilis (ATCC 6633), 
Candida albicans (ATCC 10231).
The bacterial test strains were cultured at about 35 °C for 18 to 24 hours. on soybean casein 
agar. The studied C. albicans microorganism was grown on Saburo dextrose agar at a temperature 
of about 35 °C for 24 to 48 hours.
Before starting the experiment, the purity of each culture and its typical properties were 
checked for morphological, cultural and staining (for bacteria) characteristics.
A standard pharmacopoeial turbidity sample (PSS SPU) of 10 IU was used to prepare a 
microbial suspension of standard concentration [19–21].
Studies on the specific antimicrobial action of the drug were performed in vitro by diffu-
sion into nutrient agar with the modification of the wells in accordance with the recommenda-
tions [22–25].
Acute toxicity studies were performed with single administration of the maximum possible 
amount of the drug, since known maximum toxic doses for the active substances could not be achieved.
All experiments were carried out in accordance with the Law of Ukraine “On the Protection 
of Animals against Cruelty”, which was agreed with the European Convention on the Protection of 
Vertebrate Animals of 1986 [26, 27]. Experiments were approved by the Bioethics Commission of 
the National University of Pharmacy (excerpt from protocol No. 3 of 20.04.2016). 
Acute toxicity studies were conducted on 32 adult male rats randomized to 2 subgroups for 
oral and rectal administration of the study agent. Rats from subgroup 1 were injected intragastrical-
ly with a single dose of 4.5 g of SCS-PEO suppository, which corresponded to the administration of 
10.75 mg meloxicam and 300 mg I3C per animal. Rats of subgroup 2, using a soft probe, performed 
rectal administration of the drug at a dose of 1 g, which corresponded to the administration of 
2.5 mg meloxicam and 67.7 mg I3C per animal [18].
Over the next 24 hours, the animals were continuously monitored for physiological parame-
ters. From 1 to 14 days we carried out daily assessment of the animals. The animals were removed 
according to the scheme – 4 animals from both subgroups after 1, 3, 7 and 14 days after the intro-
duction of the studied SCS-PEO by rapid decapitation.
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Physiological (measurement of basal body temperature, respiratory rate, monitoring of ac-
tivity, feed and water consumption) and morphological parameters (body and organ weight, mac-
roscopic morphological evaluation of internal organs) were used to evaluate toxicodynamics [28].
Statistical processing of the results was carried out using software using variation statistics 
methods using parametric and non-parametric methods of analysis (Student and Mann-Whitney 
criteria) and presented as comparative tables with the results of different groups as arithmetic mean 
and its error (M±m) or Median and 25 and 75 percentile (Me, LQ; UQ). Differences were consid-
ered statistically significant at p<0.05 [29].
3. Results
The results of a comparative study of the antimicrobial activity of suppository samples by 
agar diffusion (Table 1) against reference strains of bacteria and fungi showed that Sample 1, 
which includes Montanox 80 and PEO-base, has no antimicrobial effect against B. subtilis (ATCC 
6633), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538) and C. albicans (ATCC 10231). Small 
areas of inhibition of growth of E. coli (ATCC 8739) with a diameter of 13.27±0.36 mm were ob-
served, indicating little antimicrobial activity against this bacterium.
Despite the absence of a well-described mechanism of antimicrobial activity, suppositories of 
I3C (Sample 2) showed antimicrobial action against all tested microorganisms used as reference. The 
most pronounced activity was observed for S. aureus – the area of inhibition of growth of S. aureus 
(ATCC 6538) was 38.60±0.99 mm, i. e., indicates a high level of antibacterial activity. High antibacterial 
activity was also observed in relation to gram-positive B. subtilis (ATCC 6633) – the diameter of the 
growth inhibition zone was 27.83±0.77 mm. Gram-negative bacteria showed moderate sensitivity to 
Sample 2, the diameter of the zone of inhibition of growth of E. coli and purulent sticks was less than 
20 mm (Table 1). Concerning the strain of the yeast fungus C. albicans (ATCC 10231), Sample 2 showed 
a moderate antifungal effect – the diameter of the growth inhibition zone was 22.43±0.33 mm.
The severity of antibacterial and antifungal action of suppositories with I3C was not signifi-
cantly dependent on the presence (Sample 5) or absence (Sample 2) of Montanox 80. The diameter 
of the growth inhibition zones of each of the studied organisms B. subtilis (ATCC 6633), E. coli 
(ATCC 8739), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538), and C. albicans (ATCC 10231) 
for Sample 5 did not differ significantly from the values obtained for Sample 2 (Table 1).
Suppositories with meloxicam (Sample 3) did not show antimicrobial activity against the 
microorganisms B. subtilis (ATCC 6633), P. aeruginosa (ATCC 9027), S. aureus (ATCC 6538) and 
C. albicans (ATCC 10231) – no growth inhibition zones were present. About E. coli (ATSC 8739) 
had poorly expressed activity – the diameter of the growth inhibition zone was significantly smaller 
than the diameter of the growth zones of E. coli for Sample 1.
Table 1
Antimicrobial activity of tested samples of suppositories
The studied  
microorganisms
Growth inhibition zone diameter, mm (M±m, n=6)
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6
B. subtilis 
(ATCC 6633)
No zone 27.83±0.77 No zone 29.96±0.69 25.38±1.20 29.22±0.51c)
E. coli 
(ATCC 8739)
13.27±0.36 18.52±0.26 11.68±0.39а) 19.27±0.61 18.50±0.21 18.38±0.33
P. aeruginosa 
(ATCC 9027)
No zone 16.35±0.43 No zone 17.75±0.34 b) 16.87±0.45 17.65±0.31
S. aureus 
(ATCC 6538)
No zone 38.60±0.99 No zone 40.80±0.42 37.43±0.78 39.53±0.53
C. albicans 
(ATCC 10231)
No zone 22.43±0.33 No zone 20.27±0.48 b) 22.43±0.57 19.95±0.26c)
Note: а) – a significant difference (p<0.05) compared to the results of Sample 1; b) – a significant difference (p<0.05) compared to the 
results of Sample 2; c) – a significant difference (p<0.05) compared to the results of Sample 5
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The antimicrobial activity of samples of suppositories containing I3C and meloxicam did 
not differ significantly from the activity of suppositories containing only I3C. It should be noted 
that there was a certain tendency to increase the degree of antibacterial activity in the presence of 
meloxicam in suppositories, but the difference in the diameters of growth inhibition zones was only 
significant in two cases – for Samples 2 and 4 for P. aeruginosa (ATCC 9027) and for Samples 5 
and 6 regarding B. subtilis (ATCC 6633). In contrast, the antifungal activity of suppositories con-
taining I3C and meloxicam against C. albicans (ATCC 10231) was significantly lower than that of 
suppositories containing I3C only.
After a single intragastric or rectal administration of the suppository mass of SCS-PEO, 
the animals remained alive on the first day and had normal appearance and behavior. In the future, 
at all times of observation, mobility, condition of the hair, open areas of the skin, eating behavior, 
excretion did not differ from the usual for laboratory rats. There were no unusual movements, trem-
ors, and more. Body weight did not change statistically significantly over 14 days. 
The results of the study of toxicodynamics by physiological (basal temperature, respiratory 
rate, observation of activity, feed and water consumption) and morphological (mass and macro-
scopic morphological evaluation of internal organs, determination of body weight and its changes) 
indicators in rats, which were once administered with suppository SCS-PEO shown in Fig. 1. The 
data obtained during the first observation day every 6 h and in the following observation periods 
are presented: 3, 7 and 14 days.
а      b 
c d
Fig. 1. Physiological indices of rats receiving suppository mass of SCS-PEO: subgroup 1 – oral 
administration; subgroup 2 – rectal administration. For 0, 6, 12, 18, 24 hours: n=16; 3 days: n=12; 
7 days: n=8; n=4; a – animal body weight; b – basal temperature; c – respiratory rate; d – activity
At the necropsy of animals at day 14, it was noted that the hair of the animals was soft and 
shiny, the natural ostium (eyes, mouth, ears, anus and penis) were dry, without secretions, the mu-
cous membranes were shiny, pale pink.
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The location, size, density, and colour of the thymus, heart, lungs, liver, spleen, kidneys, 
prostate, testes, and vesicles did not differ from these control animals. As shown in Table 2, in all 
observation periods the mass coefficients of the organs have no significant differences with the 
reference indicators and in rats of both groups (oral and rectal administration) remained within the 
reference age norm [30].
Macroscopic morphological examination revealed that 25 % of subgroups 1 (oral adminis-
tration) rats withdrawn from the experiment at 24 h and 3 days showed gastric mucosa. This may be 
related to the effect of meloxicam, since inhibition of cyclooxygenase activity may slightly reduce 
the antacid protection of the gastric mucosa [31].
It should be noted that the calculated therapeutic dose of the SCS-PEO suppository for 
meloxicam is 0.45 mg/kg, which, respectively, for rats weighing 200–220 g is a dose of 0.09– 
0.10 mg/kg. In our study, rats in subgroup 1 received oral meloxicam at a dose of 10.45 mg. Consid-
ering that the therapeutic dosage of the study drug was exceeded more than 100 times, the mucous 
membrane hyperaemia can be considered as an expected undesirable manifestation.
Table 2
Mass ratios of organs of rats receiving suppository mass of SCS-PEO orally (subgroup 1) or rectally 
(subgroup 2) (1.10-3, n=4, Me, LQ; UQ)
Reference rate [12] 24 hours 3 days 7 days 14 days
1 2 3 4 5
Heart 
4.2  
(3.8; 4.6)
Subgroup 1 (oral administration)
4.44 (4.37; 4.48) 4.32 (4.29; 4.33) 4.28 (4.26; 4.31) 4.43 (4.41; 4.47)
Subgroup 2 (rectal administration)
4.35 (4.23; 4.46) 4.46 (4.38; 4.50) 4.25 (4.24; 4.26) 4.49 (4.42; 4.53)
Lungs 
17.6 
(15.6; 18.6)
Subgroup 1 (oral administration)
16.50 (16.27; 16.62) 16.71 (16.31; 16.97) 16.34 (15.91; 16.81) 16.30 (16.11; 16.65)
Subgroup 2 (rectal administration)
16.85 (16.47; 17.15) 16.96 (16.52; 17.22) 16.69 (16.28; 17.07) 16.50 (16.19; 16.77)
Thymus 
2.2 
(2.1; 2.3)
Subgroup 1 (oral administration)
2.17 (2.14; 2.19) 2.24 (2.19; 2.24) 2.20 (2.17; 2.22) 2.18 (2.13; 2.19)
Subgroup 2 (rectal administration)
2.11 (2.08; 2.15) 2.21 (2.13; 2.26) 2.16 (2.11; 2.21) 2.13 (2.11; 2.13)
Liver 
51.80  
(50.4; 53.2)
Subgroup 2 (rectal administration)
51.49 (50.93; 52.03) 51.67 (50.56; 52.44) 52.08 (51.67; 52.43) 51.97 (51.16; 52.53)
Subgroup 2 (rectal administration)
52.42 (51.17; 53.66) 51.76 (51.20; 52.52) 50.53 (50.26; 51.50) 51.17 (51.05; 51.34)
Spleen 
6.2  
(5.8; 6.6)
Subgroup 2 (rectal administration)
6.23 (6.17; 6.28) 5.94 (5.92; 6.05) 6.08 (5.94; 6.20) 6.15 (6.06; 6.22)
Subgroup 2 (rectal administration)
6.00 (5.95; 6.06) 6.07 (5.99; 6.11) 6.06 (6.01; 6.10) 6.32 (6.19; 6.35)
Kidneys 
16.0  
(15.6; 16.4)
Subgroup 1 (oral administration)
15.89 (15.62; 16.15) 15.87 (15.57; 16.29) 16.07 (15.91; 16.16) 16.07 (15.71; 16.36)
Subgroup 2 (rectal administration)
16.58 (16.14; 16.79) 16.65 (16.44; 16.71) 15.64 (15.63; 15.71) 16.18 (16.02; 16.24)
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Thus, SCS-PEO suppositories, which on the model of turpentine prostatitis showed a dis-
tinct prostate protective effect, showed antimicrobial properties against clinically significant agents 
of inflammation. In terms of toxicodynamics suppositories of the proposed composition can be 
considered a virtually non-toxic composition, which justifies the feasibility of further study of 
SCS-PEO as a promising prostate protector.
4. Discussion of the results
The absence of statistically significant differences of the studied indicators from the 
reference ones indicates that the degree of toxicodynamic effect of the combination of active 
components [32, 33] and the excipients [34] of SCS-PEO is consistent with the data reported 
in the literature. The results of the study on the parameters of acute toxicity indicate that 
SCS-PEO may be recommended for further preclinical study of specific prostate protective 
action, as significant toxic effects with single administration at doses exceeding the proposed 
therapeutic 3-4 times, were not detected. The proposed pharmaceutical composition based 
on polyethylene oxide based on the parameters of acute toxicity can be attributed to almost 
non-toxic substances.
Study limitations. The presence of antimicrobial activity in SCS-PEO suggests that there is 
both an additional therapeutic benefit (inhibitory effect on infectious prostatitis pathogens), and be 
a potential source of side effects (development of intestinal dysbiosis). The presence of meloxicam 
in suppositories does not significantly affect the antibacterial effect, but significantly reduces the 
antifungal activity of the pharmaceutical composition.
Prospects for further research. Given the potential risks of prolonged use, there is a need 
to consider further studies of SCS-PEO with the long-term introduction of cumulative toxic prop-
erties and adverse effects on the intestinal biotope.
5. Conclusions
The results show that suppositories with indole-3-carbinol and meloxicam meet the expect-
ed toxicity parameters.
SCS-PEO suppositories exhibit a pronounced antibacterial effect against gram-positive and 
gram-negative bacteria and antifungal action. The revealed features of antimicrobial action make it 
possible to recommend the use of SCS-PEO for the treatment of not only aseptic but also bacterial 
(infectious) forms of prostatitis.
1 2 3 4 5
Prostate
3.2 
(3.0; 3.4)
Subgroup 1 (oral administration)
3.15 (3.14; 3.18) 3.18 (3.07; 3.27) 3.21 (3.12; 3.26) 3.09 (3.07; 3.11)
Subgroup 2 (rectal administration)
3.19 (3.09; 3.27) 3.18 (3.13; 3.22) 3.11 (3.10; 3.14) 3.18 (3.12; 3.23)
Seminal vesicles 
5.1  
(5.0; 5.3)
Subgroup 1 (oral administration)
5.05 (4.99; 5.10) 5.23 (5.06; 5.33) 5.21 (5.14; 5.23) 5.23 (5.11; 5.28)
Subgroup 2 (rectal administration)
5.07 (4.99; 5.18) 5.25 (5.15; 5.29) 5.10 (5.05; 5.13) 5.15 (5.04; 5.22)
Testicular 
13.5 
(13.0; 14.0)
Subgroup 1 (oral administration)
13.70 (13.50; 13.81) 13.11 (13.06; 13.21) 13.53 (13.42; 13.60) 13.79 (13.66; 13.92)
Subgroup 2 (rectal administration)
13.57 (13.14; 13.94) 13.47 (13.32; 13.55) 13.23 (13.04; 13.60) 13.27 (13.18; 13.34)
Continuation of Table 2
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Suppositories of the combination composition with indole-3-carbinol and meloxicam on a 
polyethylene oxide basis are a relatively safe preparation and may be recommended for further 
study of the specific pharmacological action.
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